Division Director Receives 2016 Faculty Award: Research Achievement Award
The Fifth Annual Faculty Awards
by Cincinnati Children's recognized our division director, Marc E. Rothenberg, MD, PhD
, for his dedicated efforts with a Research Achievement Award. Rothenberg is one of the most productive researchers in the field of Allergy and Immunology. The scope of his work includes basic biology, translational research, genetics and epigenetics, and clinical trials of novel agents. Rothenberg primarily focuses on molecular analysis of allergic inflammation, particularly the pathogenesis of eosinophilic gastrointestinal diseases (EGIDs). He is a pioneer in identifying, studying and treating EGIDs and has built a comprehensive program, making Cincinnati Children’s the leading site for study and treatment of these disorders. He also founded and directs the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR
), a group of national leaders funded by the National Institutes of Health (NIH
). Rothenberg’s research has resulted in over 300 peer-reviewed, and in some cases landmark, articles published in the highest-impact journals. His work has been cited over 17,000 times. He has received a number of prestigious national awards, and has served as a research mentor to students and colleagues around the world. Rothenberg’s research also sheds light on other atopic diseases, including asthma. His efforts in basic research, and clinical trials, contributed to the FDA
approval in 2015 of the first new class of drugs in over a decade to treat severe asthma.
Recognized Excellence of Division Trainees and Faculty
The Division of Allergy and Immunology is proud of the excellence of its undergraduate, graduate, postdoctoral and clinical trainees and junior investigators. Several were recognized for their achievements throughout the year:
Jeffrey Rymer, predoctoral fellow in the Rothenberg Lab, won the first prize for his poster at the 2016 Annual Scientific Symposium from the Digestive Health Center.
- Jared Travers, MD, and PhD predoctoral fellow in the Rothenberg Lab, will study the role of nuclear IL-33 in mucosal inflammation through an NIH F30 fellowship grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Allergy/immunology clinical fellow, Michael Goodman, MD, received K12 support through the NIH Pediatric Scientist Development Program.
- Artem Barski, PhD, assistant professor, received a Trustee Award from Cincinnati Children's for his research project "Epigenetic Suppression of IL4 Expression in T Cells" in the Barski Lab and a T1 Core grant by the CCTST to establish the Epigenomics Data Analysis Core.
- Patricia C. Fulkerson, MD, PhD, assistant professor, selected as a 2015 Schmidlapp Woman Scholar by the Fifth Third Bank / Charlotte R. Schmidlapp Women Scholars Program to support her career development and research in the Fulkerson Lab.
- Our division's Director of Research, Simon P. Hogan, PhD, received funding from the Cincinnati Children's Research Innovation/Pilot Funding Program in 2016. This program will support the Hogan Lab in investigating the involvement of antibiotics in antigen sensitization in food allergy.
Fostering the Future through Clinical and Research Fellowship Education
David W. Morris, MD, matriculated from our division’s Allergy/Immunology Fellowship Program in the Summer of 2015. After working further as a clinician and clinical researcher at Cincinnati Children’s, Dayton Children’s Hospital recruited him to expand the clinical allergy program. During his fellowship, he conducted research mentored by Patricia C. Fulkerson, MD, PhD. He initiated two research projects in the Fulkerson Lab: 1) evaluation of human samples for eosinophil progenitor populations in the peripheral blood of patients with eosinophilic esophagitis (EoE) and 2) the development of a murine cell model to evaluate the effect of toll-like receptor 2 stimulation on eosinophil development. The former’s results published in the Journal of Allergy and Clinical Immunology
. As an indication of his excellence, his clinical and research fellowship training is supported with our division’s Allergy/Immunology T32 training award. In addition, he received a peer-reviewed grant in 2014 from the American Academy of Allergy, Asthma and Immunology (AAAAI
Tipping the Scales: the Interplay of IL-25, CD4+ TH2 Cells and Type 2 Innate Lymphoid Cells in Promoting Food Allergy
After food sensitization occurs, a strong allergic reaction to ingested food is essential for the development of food allergy. However, the immunologic mechanisms that drive the propagation of food allergic reactions in the intestine remain elusive. A recent study, led by Yui-Hsi Wang, PhD, associate professor, shows that interleukin 25 (IL-25) enhances anaphylactic responses in a mouse model of food allergy by stimulating type 2 innate lymphoid cells (ILC2s) in the intestines. ILC2s produce IL-5 and IL-13, which promote immunoglobulin E (IgE)–mediated food allergy and drive uncontrolled type-2 immune responses. Repeated exposure to the food antigen increased the number of CD4(+) T helper type 2 (TH2) cells, which fueled further IL-13 production by IL-25–stimulated ILC2s. These findings, published in the Journal of Allergy and Clinical Immunology
, suggest that the IL-25–mediated, collaborative interactions between ILCs and adaptive CD4+ TH2 cells are a pivotal step in amplifying the cascade of allergic reactions to ingested antigens and underscore the importance of understanding the mechanisms that underlie intestinal allergic responses to ingested food. Future, in-depth studies of the molecular and cellular factors composing these stepwise pathways may facilitate the discovery of biomarkers and therapeutic targets for diagnosing, preventing and treating food allergy.
Research Suggests Less Invasive Monitoring of Eosinophilic Disorder
Patricia C. Fulkerson, MD, PhD, assistant professor, led recent, preliminary research suggesting that eosinophil progenitors (EoPs) in the blood may be a potential marker for disease activity of eosinophilic esophagitis (EoE) in children. This potential method of monitoring is less invasive, sparing children with EoE the discomfort and risk of endoscopic procedures to assess whether their disease is active. The disease activity of EoE is currently monitored using peak esophageal eosinophil count, which requires invasive endoscopy to collect esophageal tissue biopsies for assessment. People with EoE, a lifelong disease, must continue monitoring disease activity, even after effective treatment with restricted diets or steroids. Treatment changes, such as reintroducing a single food, requires additional endoscopic exams to assess for disease flare-ups. Research led by the Fulkerson lab and published in the Journal of Allergy and Clinical Immunology
found elevated EoP levels in the blood of pediatric patients with active EoE disease, suggesting a promising, blood-based marker. Measuring EoP blood levels to monitor disease activity has the potential to reduce discomfort, costs and side effects for patients. However, additional research is needed to validate the EoP-based marker before its routine use in clinic.
How to Stop Eosinophilic Esophagitis Tissue Damage? Target Calpain 14
Drugs that target the protein calpain 14 may someday help treat the inflammation and scarring that can occur in people with eosinophilic esophagitis (EoE), according to new research from the Cincinnati Center for Eosinophilic Disorders
. Previous research, led by division director Marc E. Rothenberg, MD, PhD
, has established a powerful link between EoE and the CAPN14
gene, which codes for calpain 14. In the latest findings, published in JCI Insight
, Rothenberg and colleagues detail the biochemical and functional properties of calpain 14 and the disruptions in esophageal cells that occur when the expression of CAPN14
is experimentally regulated. The new information suggests that controlling the activity of calpain 14 may prevent the development of EoE, thus making the protein an important target for further drug research.
Putting the Brakes on Anaphylactic Reactions
A study, published in Immunity, Inflammation and Disease, and led by our division’s director of research, Simon P. Hogan, PhD, demonstrates that loss of the phosphatidylinositol 3-kinase (PI3K) activating signal triggered by interleukin 4 receptor alpha (IL-4R⍺) does not alter susceptibility to food-induced experimental anaphylaxis. Symptoms of experimental anaphylaxis, namely diarrhea, antigen-specific IgE and intestinal mastocytosis, are comparable between mice with, and without, functional IL-4R⍺ and PI3K signaling. However, mice without functional IL-4R⍺-mediated PI3K signaling have accelerated disease progression. This quickened anaphylactic response associates with a more rapid decrease in blood volume caused by histamine. Notably, endothelial IL-4R⍺ PI3K signaling negatively regulates the histamine-induced endothelial leak response. These results define an unanticipated role for IL-4R⍺–mediated PI3K signaling in putting the brakes on IgE-mediated anaphylactic reactions.
EoGenius Diagnostic Test for Eosinophilic Esophagitis
Research, led by division director Marc E. Rothenberg, MD, PhD
, and instructor Ting Wen, PhD, yielded an RNA expression test to help diagnose eosinophilic esophagitis (EoE). Through collaboration with Miraca Life Sciences
, they brought this innovation from the bench to bedside, and it is now commercially available as the EoGenius test
. This achievement represents a meaningful stride forward for this often misdiagnosed condition.
Kabuki syndrome is a rare developmental disorder that affects many systems of the body that associates with mutations in genes encoding histone-modifying proteins. This study, led by Andrew W. Lindsley, MD, PhD, and published in the Journal of Allergy and Clinical Immunology
, characterizes the humoral immune defects of this understudied condition in patients with mutations in lysine methyltransferase 2D (KMT2D). The research showed that mutations in KMT2D associate with dysregulation of terminal B-cell differentiation. This dysregulation is what leads to the humoral immune deficiency observed in Kabuki syndrome, and the autoimmunity that sometimes develops. These findings support the importance of a change in clinical practice in that patients with Kabuki syndrome would benefit from undergoing serial clinical immune evaluations.
Food Allergy Desensitization and Tolerance Induction
Clinical trials for the desensitization and induction of tolerance in children and adults with food allergy continued with the contributions of our division’s director of Clinical Services, Amal H. Assa’ad, MD
; physicians, such as Michelle B. Lierl, MD, and Stephanie L. Logsdon, MD
; fellows; research nurses and coordinators; and the Shubert Clinic
. Completed studies include epicutaneous immunotherapy (known as the peanut patch and marketed as Viaskin®), oral immunotherapy for peanut allergy and oral immunotherapy for multiple food allergens under the marketed name of Xolair® (omalizumab) to reduce the incidence of side effects.
Allergic Diseases and Internalizing Behaviors in Early Childhood
Research recent conducted during the fellowship of Maya Nanda, MD with the Allergy/Immunology Fellowship Program examined whether having multiple allergic diseases in early childhood associated with having internalizing disorders in the school-age years. The study was published in Pediatrics. Children who were enrolled in the Cincinnati Childhood Allergy and Air Pollution Study underwent skin testing and examinations at ages 1, 2, 3, 4, and 7 years. When the children were age 7, their parents completed the Behavior Assessment System for Children, Second Edition (BASC-2), a validated measure of childhood behavior and emotion. The study, led by Patrick H. Ryan, PhD, concluded that children with allergic rhinitis and allergic persistent wheezing at age 4 are at increased risk of internalizing behaviors at age 7. Furthermore, there was a dose-dependent association between the number of allergic diseases that a child had and the degree of elevation of the internalizing scores.
Division Director Receives First Bunning Chair
Our division director, Marc E. Rothenberg, MD, PhD
, was named the first recipient of the Denise and Dave Bunning Chair for the Division of Allergy and Immunology. Cincinnati Children’s established the chair in honor of the Bunnings, who have been generous supporters of Rothenberg’s work and the advancement of the Division of Allergy and Immunology for nearly 10 years. In particular, they have helped Cincinnati Children’s make great strides in diagnosing, understanding and treating eosinophilic gastrointestinal disease, known as eosinophilic gastrointestinal disorders (EGIDs). EGIDs cause the body to treat food like a foreign invader, causing inflammation, pain and tissue damage. Rothenberg has focused on alleviating the suffering of patients with these severe, life-altering allergies throughout his medical career. He is a pioneer in his field, leading Cincinnati Children’s as the first to form an EGID center, which stands as an example for dozens of EGID centers that have since been set up across the country. Rothenberg established and is the principal investigator of the Consortium of Eosinophil Gastrointestinal Disease Researchers
, which is one of only 22 rare disease consortia supported by the NIH
, through three NIH institutes (NIAID
). Other recent EGID achievements include Rothenberg receiving an R01 by the NIAID for his project "Genetic and Immunological Dissection of Eosinophilic Esophagitis", and the "Most Outstanding Translational Research Achievement between 2010-2015" at Cincinnati Children's for his work towards the Nature Genetics
publication, "Genome-wide association analysis of eosinophilic esophagitis provides insight into the tissue specificity of this allergic disease”. The Bunning endowed chair provides an enduring way of ensuring that Cincinnati Children's will have the best faculty and outstanding research of EGIDs in perpetuity.
BioWardrobe: an Integrated "-omics" Analysis Platform
High-throughput sequencing has revolutionized biology by enhancing our ability to perform genome-wide studies. However, due to lack of bioinformatics expertise, modern technologies are still beyond the capabilities of many laboratories. Andrey Kartashov, MSc, and Artem Barski, PhD, developed the BioWardrobe platform, which allows users to store, visualize and analyze epigenomics and transcriptomics data using a biologist-friendly web interface, without the need for programming expertise. Predefined pipelines allow users to download data, visualize results on a genome browser, calculate RPKMs (reads per kilobase per million) and identify peaks. Advanced capabilities include differential gene expression and binding analysis and creation of average tag-density profiles and heatmaps. BioWardrobe was published in Genome Biology.
Division Leading the Way to Measure Eosinophilic Esophagitis Pathology
Our division director, Marc E. Rothenberg, MD, PhD
, established and is the principal investigator (PI) of the Consortium of Eosinophil Gastrointestinal Disease Researchers (CEGIR
), which is one of only 22 rare disease consortia supported by the NIH
, through three NIH Institutes (NIAID
). CEGIR is pushing boundaries with much-needed research of eosinophil gastrointestinal diseases (EGIDs), and the management of that research as well. For instance, EGID researchers have developed and validated a histologic scoring system to objectively analyze pathologic features of eosinophilic esophagitis (EoE), a severe, often painful food allergy that renders children unable to eat a wide variety of foods. This study, led by Margaret Collins, MD
, and other professors of pathology in the Cincinnati Center for Eosinophilic Disorders
at Cincinnati Children’s was in collaboration with our national CEGIR colleagues, and published in Diseases of the Esophagus
. This scoring system encourages pathologists to evaluate more than eosinophilic inflammation and reduces our dependence on a single feature for diagnosis. By having validated tools to measure other pathologic features of EoE, the reported findings provide a new opportunity for evaluating disease activity and treatments going forward. CEGIR is also implementing cloud technology
involving a virtual microscope across consortium sites to improve collaboration between its network of researchers, providers, patients and organizations. From improving the interactions between researchers at nine different centers located across the country, to connecting patients with clinical studies and patient advocacy groups, CEGIR is leading the charge on bringing digital health to the clinical research field.
The Untold Story of a New Asthma Drug
The FDA approved the drug mepolizumab in November 2015 and then reslizumab in March 2016 to help treat severe asthma, which was an achievement grounded in many years of research and testing by innumerable physicians and scientists, including those at Cincinnati Children's, such as Division Director Marc E. Rothenberg, MD, PhD; our division's Director of Clinical Services, Amal H. Assa’ad, MD, and Director of Research, Simon P. Hogan, PhD. These medications target a subset of patients (ages 12 and up) with asthma whose current drug regimens are insufficient to control their condition. This is the first class of new asthma drugs approved in over a decade based on targeting the allergy-associated, inflammatory cells called eosinophils. Rothenberg and his research team are considered pioneers in the field, and Cincinnati Children’s has become a global leader in researching and treating eosinophilic conditions. The institution’s researchers characterized a critical genetic/molecular pathway (involving the protein interleukin 5) that helps fuel severe asthma, which is caused by eosinophils. Mepolizumab and reslizumab inhibit interleukin 5 and block the production of eosinophils, which drives certain types of severe asthma. In addition to basic laboratory studies that established the molecular target for this therapy, Cincinnati Children’s also helped conduct clinical trials testing the safety and efficacy of mepolizumab in patients, not only those with asthma but also those with other eosinophilic disorders such as eosinophilic esophagitis.
Research of a New Cell Type May Explain Why Some Individuals Develop Severe Allergic Reactions to Food
Yui-Hsi Wang, PhD, and his colleagues, report their discovery of a new cell type that appears to drive life-threatening food allergies, and may help explain why some people get severe allergic reactions, and others do not. Food allergy is a harmful immune reaction that occurs shortly after a person eats certain foods. For some people, the reaction to a particular food may merely be uncomfortable. For others, food allergy can trigger a severe, or life-threatening anaphylaxis, reaction. It has been perplexing why only some individuals among those with food allergy are more prone to develop life-threatening anaphylactic response to ingested food. A key study led by Dr. Wang, published in Immunity
, reports the findings of a new type of mucosal mast cells, termed IL-9–producing mucosal mast cells (MMC9s), which may provide some clues to this enigma. MMC9s produce large amounts of an inflammatory immune protein called interleukin 9 (IL-9) and mast cell mediators, which amplifies anaphylactic shock in response to ingested food. Data from murine experiments support that triggering MMC9s is a key step for mice to gain susceptibility to developing food allergy. Analyzing small intestine biopsy samples from patients with food allergy, Wang’s team found significantly increased expression of the IL9 genetic transcript, and other related transcripts, suggesting a possible connection. The results obtained from these studies, published in Immunity
, will likely greatly influence and improve our conceptual understandings of why some individuals may be more susceptibility to developing food allergy–induced, life-threatening anaphylaxis and thus make possible new designs for medicines to treat and/or prevent food allergy. This research will be further pursued by Dr. Wang, who received a FY 14 Peer Reviewed Medical Research Program (PRMRP
) Investigator-Initiated Research Award from the United States Department of Defense (DoD
) for his project "IL-9-Producing Mast Cell Precursors and Food Allergy".
Biosensors: Measuring Early Events in Cell Death
Natural killer (NK) cells are cytotoxic lymphocytes and first responders of the human immune system in identifying and eliminating tumor cells and virally infected cells. As natural killer (NK) cell–based therapy is being considered for treating human cancer, developing new tools to measure early events in cell death is critical. After recently demonstrating that protease-cleavable luciferase biosensors detect granzyme B and pro-apoptotic caspase activation within minutes of target cell recognition by murine cytotoxic lymphocytes, researchers led by Kimberly A. Risma, MD, PhD, successfully adapted the biosensor technology to assess perforin-dependent and -independent induction of death pathways in tumor cells recognized by human NK cell lines and primary cells and also developed biosensors for granzyme A and K, for which no other functional reporters are available. These studies, published in Blood, establish the sensitivity of protease-cleaved luciferase biosensors to measure previously undetectable events in live cells in real time. Further development of caspase and granzyme biosensors will allow interrogation of additional features of granzyme activity in live cells including localization, timing and specificity, which will inform NK cell–based therapy development.
Eosinophils Outside of Inflammation: Homeostatic Regulation of IgA Production
Eosinophils are a multifunctional type of white blood cell that resides in the gastrointestinal lamina propria. They are widely known for their roles in inflammatory response; however, their non-inflammatory functions remain largely unexplored. Researchers, led by division director Marc E. Rothenberg, MD, PhD
, used mice with a selective deficiency of systemic eosinophils (by lineage ablation) or gastrointestinal eosinophils (eotaxin-1/2 double deficient or CC chemokine receptor 3 deficient). They found that eosinophils support immunoglobulin A (IgA) class switching, maintain intestinal mucus secretions, affect intestinal microbial composition and promote the development of Peyer's patches. Eosinophil-deficient mice showed reduced expression of mediators of secretory IgA production, including intestinal interleukin 1β (IL-1β). Gastrointestinal eosinophils expressed a relatively high level of IL-1β, and IL-1β–deficient mice manifested the altered gene expression profiles observed in eosinophil-deficient mice and decreased levels of IgA(+) cells. The study’s collective data, published in Mucosal Immunology
, suggest the requirement of eosinophils for homeostatic intestinal immune responses including IgA production, and that their affect is mediated via IL-1β in the small intestine.
Neurotrophins: Another Piece in the IL-13 Inflammation Puzzle
Researchers, led by division director Marc E. Rothenberg, MD, PhD
, explored the interaction of the interleukin (IL) 13 and neurotrophin pathways, which are functionally important for the pathogenesis of immune responses, particularly those involving pain such as in eosinophilic esophagitis (EoE). By interrogating IL-13–induced responses in human epithelial cells, they found an early transcriptional target of IL-13, neurotrophic tyrosine kinase receptor, type 1 (NTRK1). NTRK1 is a cognate, high-affinity receptor for nerve growth factor (NGF). NTRK1’s induction accompanied by accumulation of activating epigenetic marks in the promoter. In human EoE, an allergic inflammation disease, NTRK1 was increased in inflamed tissue and dynamically expressed as a function of disease activity, and a downstream mediator of NTRK1 signaling was elevated in allergic inflammatory tissue compared with control tissue. Unlike NTRK1, its ligand NGF was constitutively expressed in control and disease states, indicating that IL-13–stimulated NTRK1 induction is a limiting factor in pathway activation. In epithelial cells, NGF and IL-13 synergistically induced several target genes, including chemokine (C-C motif) ligand 26 (eotaxin-3). In summary, these results, published in the Journal of Clinical Investigation Insight
, demonstrate that IL-13 confers epithelial cell responsiveness to NGF by regulating NTRK1 levels by a transcriptional and epigenetic mechanism and that this process likely contributes to allergic inflammation.